Key Highlights

• PermeaDerm demonstrated a 70% economic advantage over allograft, with mean treatment cost of US$148.70 per %TBSA versus US$497.10 for allograft

• The biosynthetic wound matrix achieved a 96% reduction in preparation time while delivering comparable clinical outcomes

• The multicenter randomised controlled study enrolled 40 patients across 11 U.S. burn centres, meeting its primary endpoint

AVITA Medical(ASX:AVH) closed at A$4.63 on 05 November 2026, rising 6.19% during the session. The S&P/ASX 200 (XJO) gained 2.61%, adding 230.60 points to close at 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, gaining 1,240.30 points to reach 35,329.10. Overnight gains on Wall Street, driven by the Democrats' decisive midterm election win, supported Equity markets globally. AVITA Medical is a therapeutic acute wound care company listed on both the ASX and NASDAQ, known for its RECELL system that creates Spray-On Skin for treating thermal burn and trauma wounds.

PermeaDerm Clinical Study Results

On 18 August 2026, AVITA Medical reported positive results from its multicenter, randomised controlled PermeaDerm-I clinical study. The study met its primary endpoint, demonstrating statistically significant superiority (p<0.001) for mean cost per percent total body surface area (%TBSA) treated. Mean treatment cost was US$148.70 for every 1% TBSA treated with PermeaDerm, compared with US$497.10 for cadaveric allograft, representing a saving of approximately US$348 per %TBSA.

As an off-the-shelf product, PermeaDerm reduced preparation time by 95.7% compared with allograft by eliminating tissue tracking, thawing, and meshing steps, while maintaining comparable application time in the operating room. Clinical outcomes were comparable between the two treatment groups, with approximately 94% of PermeaDerm patients achieving at least 95% graft take one week following autografting. All patients in both groups achieved 95% or greater wound healing by eight weeks, and no adverse events were attributed to PermeaDerm.

Study Design and Investigator Commentary

The randomised controlled study enrolled 40 patients across 11 U.S. burn centres with wounds involving up to 30% TBSA. Following excision, patients were randomised to receive either PermeaDerm or cadaveric allograft during the temporisation period before definitive split-thickness skin grafting. Study investigator Dr. Anju Saraswat noted that PermeaDerm provided clinical performance comparable to allograft with the added benefit of product transparency enabling direct visualisation of the wound bed. CEO Cary Vance stated that the data supports PermeaDerm as a modern alternative to allograft, combining comparable clinical performance with economic value and a simplified workflow.

About AVITA Medical

AVITA Medical is a leading therapeutic acute wound care company delivering solutions designed to optimise wound healing. Its portfolio includes RECELL, approved by the FDA for thermal burn and trauma wounds; Cohealyx, a collagen-based dermal matrix; and PermeaDerm, a biosynthetic wound matrix for temporary wound coverage. RECELL is also approved in Europe, Australia, New Zealand, and Japan. The company is dual-listed on the ASX (AVH) and Nasdaq (RCEL).

Sector Context

The ASX healthcare sector recorded broad gains on 05 November 2026, with medical device and therapeutic companies benefiting from the positive market environment. The global wound care market continues to grow, driven by an ageing population, increasing burn and trauma cases, and growing Demand for cost-effective treatment Options that reduce hospital stay durations and improve clinical outcomes.

Risks

AVITA Medical faces risks associated with commercial adoption of PermeaDerm in a market where allograft use is well established. The company operates in a competitive wound care market and must demonstrate value to hospital procurement departments and clinicians. Regulatory risks in international markets and the company's dependence on a relatively narrow product portfolio are additional considerations. Currency exposure from its U.S.-centric Revenue base also presents a risk for ASX investors.

Catalysts on Watch

The commercial rollout and adoption rates for PermeaDerm in U.S. burn centres will be a key metric. The company's ability to Leverage the PermeaDerm-I data to expand market penetration and potentially secure additional reimbursement support will also be monitored. Progress with RECELL's international expansion and any pipeline developments are further catalysts.

What It All Means

AVITA Medical's PermeaDerm-I study results provide clinical evidence supporting the product as a cost-effective alternative to allograft in acute wound temporisation. With a 70% economic advantage and comparable clinical outcomes, the data positions PermeaDerm as a potentially meaningful addition to the company's wound care portfolio alongside its flagship RECELL system.